Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAFV600E Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report

Overview of attention for article published in OncoTargets and therapy, August 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 1,135 followers.

RT @AngelaPassmore8: There is evidence that this combination of a BRAF inhibitor (Dabrafenib for melanoma) and a MEK inhibitor (Trametinib)…

Reply Repost Favourite